The Role of Cognitive Flexibility in Mindfulness Intervention: a Functional Near-infrared Spectroscopy Study
Launched by XINGHUA LIU · Oct 21, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the effects of mindfulness meditation on emotional distress and cognitive flexibility, which is the ability to adapt our thinking and behavior in different situations. The researchers want to understand if practicing mindfulness can help reduce feelings of emotional distress and improve cognitive flexibility. They will also be looking at how the brain changes during mindfulness exercises to see if these changes are linked to improvements in emotional well-being.
To participate in this study, individuals aged 65 to 74 years who experience emotional distress (with a score greater than 21 on a specific distress scale) and have some experience with mindfulness meditation may be eligible. However, those who have participated in mindfulness projects for more than 6 weeks before the study or who have certain mental health conditions, substance abuse issues, or difficulties with the Chinese language will not be able to join. Participants can expect to engage in mindfulness exercises and share their experiences, helping researchers learn more about the potential benefits of these practices for emotional health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects with scores greater than 21 on the Kessler Psychological Distress Scale(study 2).
- • Subjects with mindfulness experiences (study 1,only test in baseline).
- Exclusion Criteria:
- study 2:
- • Subjects who could not access the Internet; Subjects with insufficient Chinese ability; Subjects who have participated in mindfulness based projects for more than 6 weeks before, and / or the current frequency of meditation practice is more than once a week; Patients with schizophrenia or psychotic affective disorder, current organic mental disorder, substance abuse disorder and generalized developmental disorder; Subjects at risk of suicide.
- • study 1: Subjects who could not access the Internet; Subjects with insufficient Chinese ability; Patients with schizophrenia or psychotic affective disorder, current organic mental disorder, substance abuse disorder and generalized developmental disorder; Subjects at risk of suicide.
About Xinghua Liu
Xinghua Liu is a dedicated clinical trial sponsor committed to advancing medical research and innovation through rigorous and ethical study design. With a focus on enhancing patient outcomes, Xinghua Liu oversees a diverse portfolio of clinical trials across various therapeutic areas, ensuring adherence to regulatory standards and best practices. By fostering collaboration among researchers, healthcare professionals, and participants, Xinghua Liu aims to contribute valuable insights to the medical community and facilitate the development of effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Xinghua Liu
Principal Investigator
School of Psychological and Cognitive Sciences, Peking University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported